Home › Cancer (all types) › NCT00760656

Establishment of a Lifetime of Cohort of Adults Surviving Childhood Cancer

Who can join

Ages 5 and older · All sexes

Survivor Inclusion Criteria:

* Patient will have a diagnosis of childhood malignancy (or neoplasm requiring similar therapy) that was treated or followed at St. Jude Children's Research Hospital.
* Patient will be at least five years from diagnosis.
* Patient is willing to participate at any level of study
* Patient is willing to comply with the guidelines of St. Jude domiciliary care facilities
* Patient or legally authorized representative must sign informed consent for study participation.

Control Participant Inclusion Criteria:

* ≥5 years of age
* Non-first degree relatives or friends of St. Jude patients or former patients or SJCRH employees/affiliates who are not SJLIFE study team members, or family members of SJLIFE study team, or supervised by a SJLIFE study team members, or any volunteer not associated with St. Jude.
* Participant does not have a diagnosis of childhood malignancy or childhood neoplasm requiring similar therapy (i.e., diagnosed \<21 years of age).
* Participant is not currently pregnant or lactating.
* Patient is willing to comply with the guidelines of St. Jude domiciliary care facilities.
* Patient must sign informed consent for study participation.

Gait and Mobility Lab Assessment Inclusion Criteria:

* Enrolled participant in the SJLIFE study.
* At-risk for long lasting difficulties with walking or other aspects of mobility.
* Participant is not currently pregnant.
* Participant or their designee signs informed consent for Gait and Mobility Lab Assessment participation.

Survivor/Control Exclusion Criteria:

* Patient or control subject refuses to participate at any level of study

Gait and Mobility Lab Assessment Exclusion Criteria:

* Prospective participant or their designee declines participation in the Gait and Mobility Lab Assessment.

About the study

Childhood cancer predisposes to health risks that may not become apparent until many years after completion of therapy. The SJLIFE protocol is designed to establish a lifetime cohort of childhood cancer survivors treated at St. Jude Children's Research Hospital to facilitate evaluation of health outcomes in aging adults surviving pediatric cancer.

The study focuses on the following Primary and secondary objectives:

* To establish a lifetime cohort of childhood cancer survivors treated at St. Jude Children's Research Hospital to facilitate evaluation of health outcomes in aging children and adults surviving pediatric cancer. * To estimate the prevalence, cumulative incidence, and latency of selected late treatment complications following predisposing therapeutic exposures in children and adults surviving pediatric cancer. * To identify treatment, demographic, and psychosocial / behavioral related predictors of adverse health outcomes. * To develop risk profiles for adverse health outcomes across the age spectrum to guide development of clinical screening guidelines and risk-reducing interventions. * To identify factors that may be protective against the development of specific late treatment complications. * To generate data for a series of future hypothesis-driven trials * To serve as a source for the collection of samples from child and adult volunteers for future SJLIFE research. * To collect health outcomes data on a community control population for comparison purposes. * Characterize longitudinal social determinants of health (SDOH) to examine how living conditions, social integration, and structural inequality interact with personal social integrations/support to influence health.

Sponsor: St. Jude Children's Research Hospital · Participants: 10,000 · Started: Sep 13, 2007

Contact the study team

• Melissa Hudson, MD · Phone: 888-226-4343

Official record on ClinicalTrials.gov — NCT00760656

Locations in the U.S.

Conditions

• Cancer (all types)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.